Study of bosmolisib for relapsed or refractory peripheral T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental drug called bosmolisib for people with peripheral T-cell lymphoma (PTCL) that has come back or not responded to standard treatments. The goal is to see if this drug can help shrink tumors and control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of peripheral T-cell lymphoma (PTCL) that has returned or not responded to standard treatment, or you cannot tolerate standard treatment.
- You need to be well enough to carry out daily activities (ECOG performance status of 2 or less).
- Your doctor expects you to live at least 3 more months.
- You must have at least one tumor that measures 1.5 cm or more on a CT, PET/CT, or MRI scan.
- You must not have certain heart, lung, or brain conditions, and you must not be taking high-dose steroids or other immunosuppressive drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination therapy with a drug called tazemetostat for people with peripheral T-cell lymphoma that has relapsed (come back) or is refractory (did not respond to previous treatment). The goal is to see if this combination can help control the lymphoma.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial is testing two drugs, pembrolizumab and ruxolitinib, together for people with certain types of lymphoma that have come back or not responded to at least one prior treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a new combination of two pills—linperlisib and an EZH2 inhibitor—for people with a type of lymphoma called peripheral T-cell lymphoma (PTCL) that has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease with manageable side effects.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.